Kesselheim AS - Search Results

1

Buprenorphine for opioid use disorder: The role of public funding in its development.

Barenie RE, Kesselheim AS. Barenie RE, et al. Among authors: kesselheim as. Drug Alcohol Depend. 2021 Feb 1;219:108491. doi: 10.1016/j.drugalcdep.2020.108491. Epub 2020 Dec 21. Drug Alcohol Depend. 2021. PMID: 33421798

2

Preferences for and experiences with pill appearance changes: national surveys of patients and pharmacists.

Barenie RE, Kesselheim AS, Gagne JJ, Lu Z, Campbell EG, Dutcher SK, Jiang W, Sarpatwari A. Barenie RE, et al. Among authors: kesselheim as. Am J Manag Care. 2020 Aug;26(8):340-347. doi: 10.37765/ajmc.2020.44070. Am J Manag Care. 2020. PMID: 32835461

3

Public funding and the importance of reasonable pricing for buprenorphine.

Barenie RE, Kesselheim AS. Barenie RE, et al. Among authors: kesselheim as. Drug Alcohol Depend. 2021 Apr 1;221:108643. doi: 10.1016/j.drugalcdep.2021.108643. Epub 2021 Feb 20. Drug Alcohol Depend. 2021. PMID: 33642093 No abstract available.

4

Pain Management and Opioid Regulation: Continuing Public Health Challenges.

Bonnie RJ, Schumacher MA, Clark JD, Kesselheim AS. Bonnie RJ, et al. Among authors: kesselheim as. Am J Public Health. 2019 Jan;109(1):31-34. doi: 10.2105/AJPH.2018.304881. Am J Public Health. 2019. PMID: 32941766 Free PMC article.

5

Changes in Erythropoiesis Stimulating Agent Use Under a Risk Evaluation and Mitigation Strategy (REMS) Program.

Sarpatwari A, He M, Tessema FA, Gagne JJ, Kesselheim AS. Sarpatwari A, et al. Among authors: kesselheim as. Drug Saf. 2021 Mar;44(3):327-335. doi: 10.1007/s40264-020-01017-z. Epub 2020 Nov 18. Drug Saf. 2021. PMID: 33206339

6

Clinical Development Times for Biosimilars in the United States.

Lee CC, Kesselheim AS, Sarpatwari A. Lee CC, et al. Among authors: kesselheim as. Mayo Clin Proc. 2020 Oct;95(10):2152-2154. doi: 10.1016/j.mayocp.2020.06.039. Mayo Clin Proc. 2020. PMID: 33012346

7

Premarket Development Times for Innovative Vaccines--To What Extent Are the Coronavirus Disease 2019 (COVID-19) Vaccines Outliers?

Beall RF, Kesselheim AS, Hollis A. Beall RF, et al. Among authors: kesselheim as. Clin Infect Dis. 2022 Jan 29;74(2):347-351. doi: 10.1093/cid/ciab389. Clin Infect Dis. 2022. PMID: 33914860 Free PMC article.

8

Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs.

Gyawali B, Hey SP, Kesselheim AS. Gyawali B, et al. Among authors: kesselheim as. EClinicalMedicine. 2020 Apr 13;21:100332. doi: 10.1016/j.eclinm.2020.100332. eCollection 2020 Apr. EClinicalMedicine. 2020. PMID: 32382717 Free PMC article.

METHODS: This cross-sectional study of the FDA's Table of Surrogate Endpoints was conducted in May 2019. All surrogate measures listed in the FDA table as appropriate for accelerated or regular approval for breast cancer were extracted. ...FUNDING: Work on this project was …

METHODS: This cross-sectional study of the FDA's Table of Surrogate Endpoints was conducted in May 2019. All surrogate measures listed in th …

9

US Spending Associated With Transition From Daily to 3-Times-Weekly Glatiramer Acetate.

Rome BN, Tessema FA, Kesselheim AS. Rome BN, et al. Among authors: kesselheim as. JAMA Intern Med. 2020 Sep 1;180(9):1165-1172. doi: 10.1001/jamainternmed.2020.2771. JAMA Intern Med. 2020. PMID: 32897384 Free PMC article.

10

Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis.

Vokinger KN, Hwang TJ, Grischott T, Reichert S, Tibau A, Rosemann T, Kesselheim AS. Vokinger KN, et al. Among authors: kesselheim as. Lancet Oncol. 2020 May;21(5):664-670. doi: 10.1016/S1470-2045(20)30139-X. Lancet Oncol. 2020. PMID: 32359489

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results